Table 1.

Clinicopathologic variables and the expression of CD8, FoxP3, PD-1, and PD-L1 in stage IVa-b NPC patients

Variables		n	PD-1 high	p	PD-L1 high	p	CD8 high	p	FoxP3	p
Total		60	34 56.7%		55 91.7%		36 60.0%		52 86.7%
Gender	male	47	26 55.3%	0.760	42 89.4%	0.575	28 59.6%	0.988	39 83.0%	0.150
	female	13	8 61.5%		13,100%		8 61.5%		13,100%
Age	<medial	28	15 53.6%	0.795	25 89.3%	0.657	20 71.4%	0.208	26 92.9%	0.228
	≥medial	32	19 59.4%		30 93.8%		16 50.0%		26 81.3%
Pathology	WHO I	3	2 66.7%	1.000	3100%	1.000	0 0%	0.337	3100%	0.566
	WHO II	57	32 56.1%		55 91.7%		33 57.9%		49 85.9%
T stage	T1–2	4	1 25.0%	0.346	4100.0%	0.695	3 75.0%	0.314	3 75.0%	0.446
	T3	12	8 66.7%		11 91.7%		6 50.0%		12,100%
	T4	44	25 56.8%		40 90.9%		27 61.4%		37 84.1%
N stage	N1	18	11 61.1%	0.310	16 88.9%	0.853	13 72.2%	0.317	16 88.9%	0.489
	N2	25	16 64.0%		23 92.0%		15 60.0%		22 88.0%
	N3	17	7 41.2%		16 94.1%		8 47.1%		14 82.4%
TNM stage	IVa	43	27 62.8%	0.156	39 90.7%	1.000	28 65.1%	0.157	38 88.4%	0.779
	IVb	17	7 41.2%		16 94.1%		8 47.1%		14 82.4%